All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Visual abstract | QuANTUM-First trial of quizartinib with standard chemotherapy and as continuation therapy in newly diagnosed FLT3-ITD+ AML

Jul 19, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in AML

The AML Hub is happy to present a Visual Abstract summarizing key data from the phase III QuANTUM-First trial, evaluating the addition of quizartinib vs placebo to standard chemotherapy and up to three years of continuation therapy in adults aged 18–75 with newly diagnosed FLT3-ITD+ acute myeloid leukemia (AML).


 

Download this visual abstract

Click here to download this visual abstract

Download